Universal vs. Risk-Based PMAD Screening: What the Evidence Says

The Policy Question

Every practice implementing PMAD screening faces a resource allocation decision: screen every patient at every recommended time point (universal screening), or focus clinical attention on patients with identifiable risk factors (risk-based or targeted screening)?

The answer from the evidence is clear: universal screening outperforms targeted screening in both clinical sensitivity and health equity. But the implementation argument for targeted screening is not unreasonable, and understanding why universal screening is nevertheless the standard helps providers build the case for practice-level change.

---

The Case for Universal Screening

Risk factors do not reliably predict who will develop PMADs

The evidence on PMAD risk prediction is consistent: clinical risk factors identify patients at elevated statistical risk, but they perform poorly as individual predictors. Socioeconomic stress, prior psychiatric history, poor social support, and obstetric complications all correlate with elevated PMAD prevalence -- but many patients with multiple risk factors do not develop PMADs, and many patients who do develop PMADs have no identifiable risk factors.

A 2012 systematic review in Obstetrics and Gynecology (Gavin et al.) found that using risk factors alone to identify patients for screening would miss approximately 50 percent of women who develop postpartum depression. Half of affected patients would go unscreened in a purely targeted system.

This finding reflects the fundamental problem with risk-based screening for any condition with a large idiopathic or poorly-predicted fraction: selection bias built into the screening process means the screened population looks different from the total affected population.

Universal screening is equitable screening

Risk-based screening tends to systematically under-screen patients who do not fit the "at-risk" profile in the clinician's mental model. Research on implicit bias in perinatal mental health screening has documented that:

• Black and Latina patients are screened at lower rates than white patients despite higher rates of unidentified PMADs in some studies (Kozhimannil et al., General Hospital Psychiatry, 2011)
• Patients who present as high-functioning, educated, or socioeconomically stable are less likely to receive a mental health inquiry at prenatal or postpartum visits
• Patients with stoic or culturally-influenced non-disclosure styles are less likely to be identified in clinical-impression-based screening systems

Universal screening removes clinician judgment from the decision about who gets screened. Every patient at every recommended visit completes the instrument. The score -- not the clinician's impression of whether the patient "seems fine" -- drives the clinical response.

The USPSTF Grade B recommendation supports universal screening

The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women, without restriction to high-risk subgroups. This is a Grade B recommendation, meaning the evidence quality is sufficient to support routine practice recommendation.

The ACOG endorsement of universal screening with validated instruments (Practice Bulletin 343, 2023) similarly does not include a risk stratification qualifier. The recommendation is to screen, not to risk-stratify before deciding whether to screen.

---

The Argument for Targeted Screening -- and Its Limits

The resource argument

In high-volume practices, administering, scoring, and acting on EPDS forms for every patient at every prenatal and postpartum visit represents a clinical workflow investment. Targeting screening at high-risk patients appears to concentrate resources where the yield will be highest.

This argument has surface validity but fails on two counts:

First, as documented above, the high-risk identification step misses too many affected patients to be an acceptable alternative to universal screening. The efficiency gain comes at the cost of clinical accuracy.

Second, the administrative burden of universal PMAD screening is relatively modest when embedded into existing intake workflows. A 3-minute paper form administered during intake, scored by a medical assistant, and flagged to the provider adds approximately 60 to 90 seconds to the provider's direct contact time for the majority of patients (those who screen negative). This is not a prohibitive clinical burden.

The concern about false positives

Another argument for targeted screening is that universal screening increases false positives, producing unnecessary patient anxiety and clinical follow-up for patients who are not clinically affected.

The evidence does not support the clinical harm claim. Multiple studies have found no evidence that universal PMAD screening increases distress in patients who screen negative or in false-positive patients who receive clinical follow-up. For patients who are correctly identified, the harm of false reassurance through a missed screen significantly outweighs the inconvenience of a follow-up conversation for a mild false positive.

---

Implementation: What Universal Screening Requires

Universal screening is not simply a policy decision -- it requires practice infrastructure to be clinically meaningful.

What needs to be in place:

1. A standard instrument, consistently administered The EPDS is the preferred perinatal screening tool for both prenatal and postpartum settings. It should be administered at every recommended visit, not selectively.

2. A clear threshold and action protocol Every staff member who administers, scores, or encounters a completed EPDS should know: score 10 to 12 means clinical inquiry and rescreening; score 13 and above means referral; item 10 above 0 means safety assessment. This should be a written practice protocol, not undocumented individual clinical judgment.

3. A referral resource Universal screening without a referral infrastructure produces clinical documentation of problems without clinical resolution. Every practice implementing universal screening should have a specific perinatal mental health provider or practice to refer to, with confirmed insurance acceptance and telehealth availability.

4. An EHR workflow or tracking system At minimum: the ability to identify which patients have been screened, what their scores were, and whether a positive screen resulted in a referral. This does not require complex technology -- it can be a simple EHR flag or a practice-maintained log.

---

Quality Improvement Metrics

For practices implementing or improving PMAD screening programs, standard QI metrics:

| Metric | Target | |---|---| | Screening completion rate (screened / eligible visits) | ≥90% | | Positive screen rate (EPDS ≥10) | Expected 15 to 20% of screened patients | | Referral rate following positive screen | ≥80% of EPDS ≥13 patients | | Referral follow-through rate (confirmed appointment) | Track and improve over time | | Time from positive screen to confirmed appointment | Target ≤7 days |

Tracking these metrics within the practice provides both quality assurance and data for quality improvement cycles. Practices that measure screening completion rates are significantly more likely to identify gaps in their protocols and address them.

---

The Equity Argument in Summary

Universal screening is not just better medicine -- it is more equitable medicine. It removes the gatekeeping step that systematically disadvantages patients who don't match the implicit "at-risk" profile. For practices committed to equitable care for perinatal patients of all backgrounds, universal PMAD screening is one of the most straightforward structural interventions available.

The evidence supports the practice. The guidelines endorse it. The remaining work is building the workflow infrastructure to make it consistent, documented, and connected to treatment for every patient who needs it.

For a comparison of specific screening tools to use within a universal screening protocol, see our article on EPDS vs. PHQ-9 vs. GAD-7 for perinatal settings. For the referral infrastructure that makes screening clinically meaningful, see our article on building a PMAD referral pathway in an OB practice.